Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy

Cardiology in Review

Volumn 22, Issue 3, 2014, Pages 147-151

  Hartman, Joshua ^a   Frishman, William H ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; coronary heart disease; interleukin 6; tocilizumab

Indexed keywords

ACUTE PHASE PROTEIN; CANAKINUMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; ANTIINFLAMMATORY ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL DIVISION; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPERTRANSAMINASEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAST CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; REVIEW; RHEUMATOID ARTHRITIS; SKIN DEFECT; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; AGONISTS; ANIMAL; IMMUNOLOGY; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATHEROSCLEROSIS; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898601092     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000021     Document Type: Review

References (58)

1. Xu JQ, Kochanek KD, Murphy SL, et al. Deaths: fnal data for 2007. Natl Vital Stats Rep. 2010;58:1-136
2. Preventing chronic disease: a vital investment. WHO Global Report. 2005. www.who.int/entity/chp/chronic-disease-report/en/-30K. Accessed 2/27/14.
3. Heidenreich PA, Trogdon JG, Khavjou OA, et al; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
4. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310-318.
5. Libby P, Ridker PM, Maseri A. Infammation and atherosclerosis. Circulation. 2002;105:1135-1143.
6. Ross R, Glomset JA. The pathogenesis of atherosclerosis (frst of two parts). N Engl J Med. 1976;295:369-377.
7. Ross R. Atherosclerosis-an infammatory disease. N Engl J Med. 1999;340: 115-126.
8. van der Valk FM, van Wijk DF, Stroes ES. Novel anti-infammatory strategies in atherosclerosis. Curr Opin Lipidol. 2012;23:532-539.
9. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
10. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255-1262.
11. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336-1342.
12. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-defcient mice. Mol Cell. 1998;2:275-281.
13. Hannson GK. Infammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
14. Hansson G, Libby P. The role of the lymphocyte. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. New York, NY: Lippincott-Raven; 1996:557-568.
15. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinfammatory cytokines. Nat Med. 2007;13:719-724.
16. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinfammatory cytokines. Nat Med. 2007;13:719-724.
17. Yudkin JS, Kumari M, Humphries SE, et al. Infammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-214.
18. Riley E, Dasari V, Frishman WH, et al. Vaccines in development to prevent and treat atherosclerotic disease. Cardiol Rev. 2008;16:288-300.
19. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.
20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
21. Libby P, Simon DI. Infammation and thrombosis: the clot thickens. Circulation. 2001;103:1718-1720.
22. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
23. Kuller LH, Tracey R P, Shaten J, et al; MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547
24. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta analysis. Lancet. 2010;375:132-140.
25. Fibrinogen Studies Collaboration. Plasma fbrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
26. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
27. Thanassoulis G. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease. Can J Cardiol. 2013;29:30-36
28. CRP Coronary Hearth Disease Genetics Collaboration. Association between C-reactive protein and coronary heart disease: mendelian randomization analysis based on individual participant data. BMJ. 2011;342:d548.
29. Keavney B, Danesh J, Parish S, et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. Int J Epidemiol. 2006;35:935-943.
30. Fantuzzi G, Zheng H, Faggioni R, et al. Effect of endotoxin in IL-1 beta-defcient mice. J Immunol. 1996;157:291-296.
31. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-defcient mice. Proc Natl Acad Sci USA. 1997;94:8093-8098.
32. Harris TB, Ferrucci L, Tracy R P, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
33. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6:315-325.
34. Späth-Schwalbe E, Born J, Schrezenmeier H, et al. Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab. 1994;79:1212-1214.
35. Ando T, Rivier J, Yanaihara H, et al. Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats. Am J Physiol. 1998;275(5 pt 2):R1461-R1467.
36. Karalis K, Louis JM, Bae D, et al. CRH and the immune system. J Neuroimmunol. 1997;72:131-136.
37. Eddahri F, Denanglaire S, Bureau F, et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood. 2009;113:2426-2433.
38. Neumann FJ, Ott I, Marx N, et al. Effects of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arter Throm Vasc Biol. 1997;17:3399-3405.
39. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994;179:1253-1259.
40. Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992;215:356-362.
41. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351: 2611-2618.
42. Kuo CC, Gown AM, Benditt E P, et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501-1504.
43. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(10 suppl 1):S9-S14.
44. Houssiau FA, Devogelaer J P, Van Damme J, et al. Interleukin-6 in synovial fuid and serum of patients with rheumatoid arthritis and other infammatory arthritides. Arthritis Rheum. 1988;31:784-788.
45. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
46. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
47. Huber SA, Sakkinen P, Conze D, et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364-2367
48. IL6R Genetics Consortium and Emerging Risk Factor Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213.
49. Oldfeld V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69:609-632.
50. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocili-zumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-2980.
51. Protogerou AD, Zampeli E, Fragiadaki K, et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219:734-736
52. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6 MR) Consortium. The interleukin-6 receptor as a target for pre vention of coronary heart disease: a mendelian randomization analysis. Lancet. 2012; 379:1214-1224.
53. Smolen JS, Beaulieu A, Rubbert-Roth A, et al; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-997.
54. Gabay C, Emery P, van Vollenhoven R, et al; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541-1550.
55. Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229:174-181.
56. Ridker PM. Testing the infammatory hypothesis of atherothrombosis: sci-entifc rationale for the cardiovascular infammation reduction trial (CIRT). J Thromb Haemost. 2009;7(suppl 1):332-339.
57. Everett BM, Pradhan AD, Solomon DH, et al: Rationale and design of the Cardiovascular Infammation Reduction Trial: a test of the infammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199-207.
58. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-infammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605.